Loading…
GRI
GRI Bio, Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 3622AW502
$1.92-7.25%Price as of Aug 29, 18:50 UTC · updated once a day, after the close
Key metrics
- Market cap
- $4.2M
- P/E
- —
- Forward P/E
- —
- P/B
- 0.4x
- Dividend yield
- —
- Payout
- —
- EPS
- -$2.83
- ROE
- -142.02%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- -0.66
- 52-week high
- $80.36
- 52-week low
- $1.36
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -100.0% over 5Y.
today you would have $0.00▼ -100.0%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $6.92 | $394.13 | $16,676.66 | $376,849.19 | |
| P/B | 1.8x | 0.6x | 1.8x | 6.7x | — |
| EPS | -$121.80 | -$1,545.55 | -$125,355.77 | -$47,308.82 | |
| ROE | -203.55% | -199.00% | -203.55% | -5033.59% | — |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| JAGXJaguar Health, Inc. | $0.81 | 0.0x | — | — | -548.83% | $4.19M |
| REVBRevelation Biosciences Inc | $1.05 | 0.0x | 0.4x | — | -154.77% | $4.18M |
| XRTXXORTX Therapeutics Inc. | $2.34 | — | 1.6x | — | -99.24% | $4.25M |
| APVOAptevo Therapeutics Inc. | $2.37 |
About the company
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
- 3
- La Jolla, United States
Company description provided by Yahoo Finance.